COLTRO, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.891
AS - Asia 1.573
EU - Europa 1.473
SA - Sud America 193
AF - Africa 26
OC - Oceania 23
Totale 5.179
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.863
RU - Federazione Russa 742
CN - Cina 516
SG - Singapore 445
IT - Italia 243
HK - Hong Kong 238
KR - Corea 185
BR - Brasile 155
IE - Irlanda 124
SE - Svezia 74
FI - Finlandia 71
CH - Svizzera 61
DE - Germania 59
VN - Vietnam 59
IN - India 46
FR - Francia 27
GB - Regno Unito 26
AU - Australia 23
ID - Indonesia 22
NL - Olanda 20
JO - Giordania 18
AR - Argentina 17
CA - Canada 14
MX - Messico 9
JP - Giappone 7
CI - Costa d'Avorio 6
AT - Austria 5
BJ - Benin 5
ES - Italia 5
MA - Marocco 5
PH - Filippine 5
ZA - Sudafrica 5
BD - Bangladesh 4
EC - Ecuador 4
PY - Paraguay 4
UA - Ucraina 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
CO - Colombia 3
IQ - Iraq 3
KZ - Kazakistan 3
LB - Libano 3
PL - Polonia 3
TR - Turchia 3
UZ - Uzbekistan 3
BO - Bolivia 2
IL - Israele 2
JM - Giamaica 2
LU - Lussemburgo 2
SA - Arabia Saudita 2
TN - Tunisia 2
UY - Uruguay 2
VE - Venezuela 2
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
HN - Honduras 1
HU - Ungheria 1
LT - Lituania 1
LV - Lettonia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
YT - Mayotte 1
Totale 5.179
Salva come PNG Salva come JPEG
Città #
Santa Clara 698
Singapore 327
Ashburn 232
Hefei 213
Hong Kong 207
Seoul 185
Dublin 124
Fairfield 81
Moscow 74
Chandler 68
Bern 61
Beijing 59
Kent 43
Los Angeles 41
Buffalo 37
Woodbridge 37
Cambridge 36
Seattle 35
Florence 34
Helsinki 33
Munich 32
Altamura 31
Lawrence 30
Turku 28
Dallas 26
Houston 25
Ho Chi Minh City 24
Mumbai 24
Melbourne 23
Wilmington 23
New York 20
Shanghai 20
Paris 18
Princeton 18
Boston 17
Jakarta 16
São Paulo 16
London 14
Milan 14
Hanoi 12
Washington 12
Ann Arbor 11
Bengaluru 11
Falkenstein 9
Lappeenranta 9
Brooklyn 8
Sesto Fiorentino 8
Siena 8
Bremen 7
Tianjin 7
Abidjan 6
Montreal 6
Pian di Scò 6
Rio de Janeiro 6
Tokyo 6
West Jordan 6
Yubileyny 6
Boardman 5
Cervia 5
Chennai 5
Chicago 5
Cotonou 5
Fiesole 5
Medford 5
Modena 5
San Diego 5
The Dalles 5
Castel Maggiore 4
Clifton 4
Hillsboro 4
Napoli 4
Pune 4
Redondo Beach 4
San Jose 4
Toronto 4
Altopascio 3
Amsterdam 3
Atlanta 3
Belo Horizonte 3
Casablanca 3
Chengdu 3
Curitiba 3
Düsseldorf 3
Frankfurt am Main 3
Hangzhou 3
Johannesburg 3
Mexico City 3
Romola 3
Tashkent 3
Thành Phố Bà Rịa 3
Vienna 3
Almaty 2
Altenberg bei Linz 2
Amman 2
Andover 2
Biên Hòa 2
Bogotá 2
Buenos Aires 2
Bắc Ninh 2
Cagliari 2
Totale 3.336
Salva come PNG Salva come JPEG
Nome #
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 211
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 184
A life-threatening ruxolitinib discontinuation syndrome 175
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 169
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 163
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 162
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 152
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 150
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 144
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 144
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 142
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients 139
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 138
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients 137
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 137
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 133
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 130
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 127
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions 124
Mutations and thrombosis in essential thrombocythemia 124
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 120
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients 118
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 116
Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Adult Patients 115
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 112
Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases 110
Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms 110
Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment 110
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 106
Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia 106
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis 101
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 101
Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP 100
The safety of JAK kinase inhibitors for the treatment of myelofibrosis 98
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 97
A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement 96
Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) 94
Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis 92
Thrombotic risk correlates with mutational status in true essential thrombocythemia 89
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib 87
Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients 81
Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms 81
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis (RCO) Score in Primary Myelofibrosis 41
Totale 5.266
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.758
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.758
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202148 0 0 0 0 0 6 3 10 9 8 9 3
2021/2022110 2 1 3 1 4 5 0 22 14 1 23 34
2022/2023559 34 87 36 23 56 90 69 21 35 15 16 77
2023/2024445 18 25 56 18 39 75 11 79 12 50 43 19
2024/20252.227 57 206 122 318 562 341 80 107 82 81 129 142
2025/20261.623 304 419 383 263 247 7 0 0 0 0 0 0
Totale 5.266